HH
Therapeutic Areas
InflaRx Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vilobelimab (GOHIBIC) | Critical COVID-19 (SARS-CoV-2-induced ARDS) | Marketed (EUA) |
| Vilobelimab | Pyoderma Gangrenosum | Phase 3 |
| Izicopan | Hidradenitis Suppurativa | Phase 2a |
| IFX002 | Chronic Inflammatory Indications | Preclinical |
Leadership Team at InflaRx
PD
Prof. Dr. Niels C. Riedemann
Chief Executive Officer and Founder
PR
Prof. Renfeng Guo, M.D.
Chief Scientific Officer and Founder
DT
Dr. Thomas Taapken
Chief Financial Officer
CC
Camilla Chong, M.D.
Chief Medical Officer
NB
Nicole Bertsch
Senior Director, Head of Human Resources
KB
Kofi Boaten
VP, Head of Supply Quality & Clinical Trial Supplies
KC
Kirsten Cremering
Senior Director, Head of Quality Assurance
PE
Petra Eßer
VP, Head of Finance and Controlling
DM
Dr. Maria Habel
VP, Head of preclinical R&D and QC
DP
Dr. Peter Hurt
Senior Director, Head of Drug Safety and Pharmacovigilance